United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 124.9% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 45,185 shares of the life sciences company’s stock after purchasing an additional 25,094 shares during the period. Illumina makes up approximately 2.0% of United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s portfolio, making the stock its 26th biggest holding. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Illumina were worth $16,635,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently made changes to their positions in ILMN. Next Capital Management LLC acquired a new stake in Illumina during the 2nd quarter worth about $25,000. Strategy Asset Managers LLC acquired a new stake in Illumina during the 1st quarter worth about $26,000. Mizuho Securities Co. Ltd. acquired a new stake in Illumina during the 1st quarter worth about $37,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Illumina during the 2nd quarter worth about $37,000. Finally, Trustcore Financial Services LLC acquired a new stake in Illumina during the 2nd quarter worth about $44,000. 92.09% of the stock is currently owned by institutional investors.
Several equities research analysts have weighed in on ILMN shares. UBS Group increased their price target on Illumina from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, August 20th. Bank of America downgraded Illumina from a “buy” rating to an “underperform” rating and set a $310.00 price target on the stock. in a research report on Friday, July 12th. Canaccord Genuity downgraded Illumina from a “buy” rating to a “hold” rating and cut their price target for the stock from $330.00 to $300.00 in a research report on Tuesday, July 30th. Finally, Argus dropped their target price on Illumina to $340.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $330.92.
In related news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $288.36, for a total value of $951,588.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $285.52, for a total transaction of $2,855,200.00. Following the completion of the transaction, the senior vice president now directly owns 86,585 shares in the company, valued at $24,721,749.20. The disclosure for this sale can be found here. Insiders have sold a total of 60,458 shares of company stock worth $19,329,754 over the last 90 days. Insiders own 0.38% of the company’s stock.
Shares of NASDAQ:ILMN traded down $9.08 during trading on Friday, reaching $279.44. 995,369 shares of the company’s stock traded hands, compared to its average volume of 987,484. Illumina, Inc. has a fifty-two week low of $268.62 and a fifty-two week high of $380.76. The company has a quick ratio of 6.10, a current ratio of 6.79 and a debt-to-equity ratio of 0.42. The firm has a market cap of $42.42 billion, a PE ratio of 48.85, a P/E/G ratio of 2.69 and a beta of 1.10. The company has a 50-day simple moving average of $306.60 and a 200-day simple moving average of $315.14.
Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.03. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The firm had revenue of $838.00 million for the quarter, compared to analysts’ expectations of $835.12 million. During the same period last year, the firm earned $1.43 EPS. The company’s quarterly revenue was up 1.0% on a year-over-year basis. On average, equities research analysts forecast that Illumina, Inc. will post 6.04 EPS for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: What is Green Investing?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.